XBiotech Inc. (NASDAQ:XBIT) saw an uptick in trading volume on Friday . 213,374 shares changed hands during trading, an increase of 29% from the previous session’s volume of 164,780 shares.The stock last traded at $13.50 and had previously closed at $14.26.

A number of brokerages have recently issued reports on XBIT. Zacks Investment Research lowered shares of XBiotech from a “hold” rating to a “sell” rating in a research report on Saturday, August 20th. Noble Financial restated a “buy” rating and set a $30.00 target price (up from $24.00) on shares of XBiotech in a research report on Tuesday, June 28th.

The company’s market capitalization is $424.34 million. The firm has a 50 day moving average of $15.19 and a 200 day moving average of $13.12.

XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of diseases. The Company focuses on bringing its lead product candidate, Xilonix (MABp1), to market. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.